More PID diagnostic tests included in the WHO EDL
For the second year in a row, tests for diagnosing primary immunodeficiencies (PIDs) have been included in this Model List.
For the second year in a row, tests for diagnosing primary immunodeficiencies (PIDs) have been included in this Model List.
In the last 24 months, IPOPI undertook a thorough and comprehensive process to develop its new 5-year strategic plan for the 2021-2025 period.
IPOPI launched the COVID-19 Learning Expedition (LEX) in July 2020, to identify, analyse and provide recommendations on issues brought about by the COVID-19 pandemic for patients with primary immunodeficiency (PID).
An interactive tool built on 6 key principles of care that measures the status of the PID healthcare environment across the globe
Belgium
Avenue Louise/Louizalaan 65, Bte 11
BE-1050 Brussels, Belgium
IPOPI aisbl is an international non-profit association registered in Belgium
Numéro d’entreprise
BE 0761.784.055
Email: info@ipopi.org
Tel: +32 2 790 73 66 (Belgium)